3 results
Not approvedWill not start
The primary objective of this secondary prevention study is to evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics of gantenerumab, an anti-amyloid antibody, in amyloid-positive, cognitively unimpaired participants at risk for or…
Approved WMOCompleted
This study will evaluate the efficacy and safety of gantenerumab compared with placebo in patients with early (prodromal to mild) Alzheimer's disease (AD).
Approved WMOPending
Aim of this study is to compare the effects of mannitol and HS in equimolar concentrations on cerebral blood flow, cerebral oxygenation, metabolism and inflammation in patients with severe TBI.